Young America’s Foundation has been sued in India by a leading Indian pharmaceutical company over the development of a new form of the generic form of its drugs.
The foundation is accused of breaching the provisions of the Indian Pharmaceutical Regulatory Authority (IPRA) by using the same company that developed the drug to develop its own drug.
According to an Indian media report, the Indian Government is now threatening to take legal action against the foundation if it does not take immediate steps to stop the alleged violation of the provisions.
The report said the foundation’s chairman, Anurag Thakur, has been in the news recently for his anti-drug campaign in which he has criticised pharmaceutical companies in India, claiming that they are not interested in the wellbeing of people, and that they only sell drugs.
He has also criticised the Indian Medical Association (IMA), which has called for a boycott of pharmaceutical products.
The Indian Government’s stance has come in the wake of the controversy surrounding the use of Indian pharmaceutical companies to develop drugs in the country.
In November, the IMA had called for the government to “reconsider” its decision to import the anti-depressant Zoloft from India.
On Wednesday, Indian Minister for Health Dr Gopal Baglay said the government is taking legal action “against those who have violated the Indian Pharmacopeia and the law”.
The Indian government should reconsider its decision,” he said in a statement. “
I am calling upon our pharmaceutical industry to stop its drug manufacturing and distribution in India.
The Indian government should reconsider its decision,” he said in a statement.
India has become one of the biggest buyers of pharmaceuticals, with the country’s GDP expected to grow to $1.3 trillion in 2020 from $1 trillion in 2017.
The report says that the foundation has also violated a section of the Pharmaceutical Act of India, which states that a foundation may not “distribute or import a drug” without the approval of the government.
“The Foundation of Young America has been using the name of Young India Foundation for a long time, but now it is being exposed,” said Anil Sharma, president of Young Americans Foundation India.
According to the report, in June 2015, the foundation launched a “drug” called N-2, which is a generic version of the anti-[2-(4-chlorophenoxy)-1-amine]-3-yl]-2-methylimidazolium chloride (AMCP-1) drug, which has been used to treat bipolar disorder and bipolar depression.
In January 2016, it also launched a generic drug called Ameliorate, which it said is a “powerful drug” to treat patients with ADHD and is already used in India to treat people with depression.